Building confidence in clinical trial data and technology processes

For example, a large trial using data from multiple electronic health records (EHRs), wearables, and lab systems can be derailed if an EHR integration is misconfigured. Missing adverse event data can trigger regulatory queries, delaying readouts and patient access to therapies.

While the industry recognizes the need for robust testing and validation before live patient data entry, achieving this is hard given many platforms, vendor relationships, and evolving data standards. The key question: How can pharma technology and clinical ops leaders establish a reliable, repeatable data validation capability that prevents downstream issues?

With hefty costs from data issues found late, it is no longer viable to find problems at database lock. Studies must now simulate and validate full data flows before enrolling the first patient. This requires investing in robust test databases and realistic samples that reflect real-world study complexity. Organizations prioritizing early, thorough testing consistently perform better on timelines and budgets.

Build a robust validation capability

In our experience with major CROs and sponsors, we have found that six key behaviors support effective data validation systems throughout a study's lifecycle. Leaders should focus on making validation a scalable, repeatable strategic capability, not just a set of steps.

There are several key actions that technology and clinical operations leaders can take together:

1. Foster an end-to-end data quality culture

Executives should create the expectation that teams understand and document the data journey from source to submission as a foundational discipline at the study level, and more broadly within their scope of responsibility. This capability can start with study-specific tasks like mapping the movement of data in systems at a study level. For example, a study might include a workflow where demographic data is captured at the site, laboratory results are updated nightly, and daily symptom reports come from a mobile app. Mapping this flow uncovers that lab data sometimes arrives before the corresponding patient record is created or updated in the electronic data capture system, potentially causing data mismatches or perceived inaccuracies.

This approach, and the underlying mindset it promotes, helps to identify vulnerabilities at every interface, establishing quality by design in business processes, not just technology projects.

2. Institutionalize rigorous data standards

Making clear, precise data specifications an enterprise-wide standard reduces ambiguity and fosters consistency across studies. It should be standard practice to systematically document data fields, variables, and mappings in a study with unambiguous definitions, format expectations, controlled terminologies, and edit checks. For instance, before live data is entered, a team could use a centralized data specifications document that defines exactly how each data point should be recorded, stored, and transferred between systems.

This type of centrally governed specification ensures repeatable excellence, acting as a bridge between operational needs and regulatory demands.

3. Invest in synthetic and AI-based data validation tools

Leveraging the latest technologies is a key way to generate robust, privacy-safe datasets that mirror real-world complexity. Emerging artificial intelligence-based tools can generate synthetic datasets including realistic visit schedules, missing data, outlier values, and rare adverse events without regulatory baggage. As this capability matures, synthetic datasets will become central to representative and meaningful validation.

Executives who equip teams with advanced tools enable organization-wide, scalable validation practices that consistently manage edge cases and unusual scenarios, long before real patient data enters the picture.

4. Require comprehensive, real-world simulation for every study

Rather than seeing simulation as a “nice to have,” executives should make end-to-end, scenario-based testing a mandatory gate in study startups. End-to-end testing should be part of standard study startup, not a post-hoc catch-up activity. Simulation, then, becomes embedded in workflows and expectations, turning risk mitigation into a norm rather than an exception.

For instance, before live patient data is collected, a team could conduct a full simulation of the data journey using synthetic datasets that include realistic visit schedules, missing data, outlier values, and rare adverse events. This simulation would test every interface and process, from data entry through transfer, storage, and analysis, ensuring that all systems and teams are prepared to handle real-world complexity and edge cases. By identifying vulnerabilities and process gaps early, organizations can proactively address issues, reducing the risk of late-stage surprises and regulatory setbacks.

5. Automate, document, and learn continuously

Automating validation and maintaining detailed, auditable records transforms compliance into efficiency and learning. This administrative effort can be considered a long-term investment in organizational memory and improvement, exceeding simple checklist compliance and building resilience against turnover or scale-up challenges. It also produces a living knowledge base that not only meets compliance needs but also underpins long-term organizational learning and process improvement.

6. Build cross-functional governance structures

Data validation is not an information technology (IT)-only function. Executives should create integrated, cross-functional teams that include clinical operations, IT, data management, quality assurance, and external partners. This governance structure should be empowered to set strategy, oversee execution, and evaluate outcomes, so that all stakeholders contribute to and benefit from strong data validation capabilities.

Ideally, data validation and testing should be elevated to a dedicated, cross-disciplinary function. Depending on the organization and operating model, it may fit well within data management, clinical operations, and digital/IT. It should be overseen by a governance committee or center of excellence that brings together expertise from clinical, technical, quality, compliance, and vendor management domains.

This embeds data validation as a repeatable, core competency and ensures its alignment with organizational goals, regulatory requirements, and continuous improvement initiatives. This approach also protects the capability from being siloed within projects and supports its evolution with both technological and regulatory changes.

We urge clinical operations leaders and your technology partners to consider: What issues in our last study were discovered late? Which could have been identified by end-to-end testing? Who in our organization is accountable for validating the entire data journey, not just individual systems?

Ultimately, the data and technology systems validation capability can become a strategic differentiator that enables faster trials, higher data quality, and superior regulatory readiness as study complexity grows. The reward for this effort is a data ecosystem ready to face regulatory scrutiny and drive confident decision-making.

This article was first published in Applied Clinical Trials.